Evidence map›Paper›PMID 41094194›Full record

ArticleThe Journal of antibiotics2026

Olorofim, a potential novel drug candidate against Helicobacter pylori infection.

Saba Ghaffari, Maryam Esmaeili, Marjan Mohammadi

Abstract read
PubMed Publisher
In one paragraph

Article in The Journal of antibiotics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Saba GhaffariHPGC Research Group, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Maryam EsmaeiliHPGC Research Group, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Marjan MohammadiHPGC Research Group, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran. marjan.mohammadi2010@gmail.com.

Funding

Pasteur Institute of Iran (IPI) #2092, IR.PII.REC.1401.022
6 · The paper itself

Abstract

Helicobacter pylori infection is widely prevalent and can lead to peptic ulcer disease and gastric cancer. Treatment is challenged by a growing rate of antibiotic resistance. In this study, we evaluated the efficacy of olorofim (F901318), a DHODH inhibitor against Aspergillus fumigatus, in targeting H. pylori. The minimum inhibitory concentration (MIC) of olorofim against H. pylori reference and three multiple drug-resistant strains was determined. The nature of its growth inhibitory effect was assessed using liquid and solid bacterial culture. The general toxicity of olorofim was assessed against other bacteria and reassessed against eukaryotic cells. The effect of olorofim on DHODH activity was tested using a substrate reduction assay. Pairwise sequence alignment was carried out on H. pylori and A. fumigatus DHODH amino acid sequences. The MIC of olorofim against H. pylori reference strain and three MDR strains ranged from 0.075 to 0.625 µg mL

Indexed as

Anti-Bacterial AgentsHelicobacter InfectionsHelicobacter pyloriPyrrolesSulfonamidesAspergillus fumigatusDrug Resistance, Multiple, BacterialHumansMicrobial Sensitivity Tests1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineAnti-Bacterial AgentsPyrrolesSulfonamides

Identifiers

PMID41094194

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.